{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-305886","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2022-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.944900+00:00","generated_at":"2026-06-21T04:06:32.279297+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Akebia CAO Violetta Cotreau to resign; CFO David Spellman named principal accounting officer","bullets":["Violetta Cotreau resigns as Chief Accounting Officer, effective Dec 30, 2022, to pursue new career opportunity.","David A. Spellman, currently CFO, appointed as principal accounting officer effective Dec 30, 2022.","Spellman has over two decades of biopharma finance experience; previously at Vertex, Intarcia, and Mersana.","Spellman will continue as CFO and Treasurer in addition to the principal accounting officer role."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-305886","json":"https://secwatch.observer/filing/0001193125-22-305886.json","markdown":"https://secwatch.observer/filing/0001193125-22-305886.md","text":"https://secwatch.observer/filing/0001193125-22-305886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522305886/0001193125-22-305886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522305886/d412372d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:06:32.279297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59faa76f84","claim":"Violetta Cotreau resigned as Chief Accounting Officer at Akebia Therapeutics, Inc..","evidence_excerpt":"On December 14, 2022, Violetta Cotreau, Chief Accounting Officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of her intent to resign to pursue a new career opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522305886/0001193125-22-305886-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"6bf21b3b58","claim":"David A. Spellman was appointed as principal accounting officer at Akebia Therapeutics, Inc..","evidence_excerpt":"The Board of Directors of the Company has appointed David A. Spellman, the Company’s Chief Financial Officer, as principal accounting officer, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312522305886/0001193125-22-305886-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}